Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ethinyl Estradioll/Levonorgestrel · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| EE/LNG | EXPERIMENTAL | - |
| BEM/RZR | EXPERIMENTAL | - |
| BEM/RZR + EE/LNG | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ethinyl Estradioll/Levonorgestrel (EE/LNG) | DRUG | Treatment-A (EE/LNG): A single 0.03 mg/ 0.15 mg dose of EE/LNG (1 × 0.03 mg/ 0.15 mg tablet) will be administered in the morning under fasting conditions on Day 1. |
| Bemnifosbuvir/Ruzasvir (BEM/RZR) | DRUG | Treatment-B (BEM/RZR): A 550 mg/180 mg dose of BEM/RZR (2 × 275 mg/90 mg BEM/RZR FDC tablets) will be administered once daily (QD) under fasting conditions on Days 8 to 14. |
| Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) | DRUG | Treatment-C (BEM/RZR + EE/LNG): BEM (550 mg)/ RZR (180 mg) as 2 × 275 mg/90 mg BEM/RZR FDC tablets will be administered QD in the morning under fasting conditions on Days 15 to 19. A single 0.03 mg/0.15 mg dose of EE/LNG (1 × 0.03 mg/ 0.15 mg tablet) will be concomitantly administered with BEM/RZR on the morning of Day 15. |
Inclusion Criteria: * Healthy post-menopausal or hormonally sterile female * Minimum body weight of 50 kg and body mass index (BMI) of 18.0-30 kg/m2. * Willing to comply with the study requirements and to provide written informed consent. Exclusion Criteria: * Infected with hepatitis B virus, hep...
Ethinyl Estradiol/Levonorgestrel is an oral contraceptive combination used in a healthy volunteer study to evaluate potential drug-drug interactions with the investigational antiviral Bemnifosbuvir/Ruzasvir (BEM/RZR). The study enrolled 24 female participants aged 18 years and older in Canada.
Ethinyl Estradiol/Levonorgestrel is being studied by Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) as part of a drug-drug interaction trial with their investigational antiviral Bemnifosbuvir/Ruzasvir. The study is a Phase 1 clinical trial conducted in healthy female volunteers.
Ethinyl Estradiol/Levonorgestrel is in Phase 1 clinical development as part of a drug-drug interaction study. The trial, NCT07272889, has been completed. The drug is investigational in this context and not approved for this specific study use.
Ethinyl Estradiol/Levonorgestrel is associated with one completed Phase 1 clinical trial, NCT07272889, titled 'Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)'. The study enrolled 24 healthy female participants in Canada.
Yes, Ethinyl Estradiol/Levonorgestrel is commonly abbreviated as EE/LNG. In the clinical trial NCT07272889, it is studied in combination with the investigational antiviral Bemnifosbuvir/Ruzasvir (BEM/RZR) to assess potential drug-drug interactions in healthy female volunteers.